Abstract
Background The cytotoxic activity of the pyridazin-3-one derivative LCS-1 was previously suggested
to be due to the inhibition of superoxide dismutase 1 (SOD1). However, no direct evidence
was provided that LCS-1 inhibits SOD1 within cells.
Methods In this study, we investigated the cytotoxic activity of LCS-1 against bloodstream
forms of Trypanosoma brucei, a protozoan parasite that does not express copper/zinc-containing SOD1, but an iron-containing
superoxide dismutase (FeSOD).
Results At 250 µM, LCS-1 did not inhibit the activity of FeSOD in cell lysates of bloodstream
forms of T. brucei, confirming that the compound is a specific inhibitor of SOD1. However, LCS-1 displayed
substantial trypanocidal activity with a minimum inhibitory concentration of 10 µM
and a half-maximal effective concentration of 1.36 µM, indicating that the cytotoxic
action of the compound cannot solely be due to inhibition of SOD1.
Conclusion The results of this study is an important finding as it shows that LCS-1 has more
than one cytotoxic mode of action.
Key words
anticancer drugs - drug research - pharmacology